КФУ. Карточка публикации. Cilostazol ameliorates liver fibrosis in a MASLD animal model; potential involvement of liver sinusoidal endothelial cell protection.

RUS

- EN
- 中文
- ES

CILOSTAZOL AMELIORATES LIVER FIBROSIS IN A MASLD ANIMAL MODEL; POTENTIAL INVOLVEMENT OF LIVER SINUSOIDAL ENDOTHELIAL CELL PROTECTION.

Форма представления

Тезисы и материалы конференций в зарубежных журналах и сборниках

Год публикации

2026

Авторы, сотрудники КФУ

Арсланова Алиса Наилевна, автор

Хуснуллина Алина Ринатовна, автор

Другие авторы

Хисанори Гото, Куми Кимура, Ясухико Ямамото, Тошинари Такамура

Авторы, аспиранты КФУ

Арсланова Алиса Наилевна, автор

Хуснуллина Алина Ринатовна, автор

Библиографическое описание на языке оригинала

A. Arslanova; A. Khusnullina; H. Goto; K. Kimura; Y. Yamamoto; T. Takamura. Cilostazol ameliorates liver fibrosis in a MASLD animal model; potential involvement of liver sinusoidal endothelial cell protection. MASLDモデルにおけるシロスタゾールの肝線維化改善と肝類洞内皮細胞保護の可能性. Abstracts. 39th Annual Scientific Meeting of the Japanese Society for Diabetes and Obesity in Animals. p.79 (82)

Аннотация

Metabolic dysfunction-associated steatotic liver disease (MASLD) ? and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH) ? leads to injury of liver sinusoidal endothelial cells (LSECs) as a key driver of disease progression. The integrity of LSECs is essential for hepatic microvascular homeostasis, and their dysfunction may exacerbate parenchymal injury and fibrogenesis. Cilostazol, a phosphodiesterase-3 inhibitor, has demonstrated endothelial protective effects, enhancing endothelial function, reducing apoptosis, and modulating vasoactive mediators such as nitric oxide. However, it remains unknown whether cilostazol can similarly protect LSECs and thereby attenuate hepatic fibrosis in MASLD/MASH. We therefore investigated whether cilostazol mitigates liver fibrosis in a murine MASLD model complicated by diabetes, with a particular focus on the preservation of LSEC integrity. Mice were induced to develop MASH plus diabetes by combined feeding of a high-fat d

Ключевые слова

MASLD, MASH, liver fibrosis, type 2 diabetes, cilostazol

Место издания

Нагойя

Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на эту карточку

https://repository.kpfu.ru/?p_id=324338

Полная запись метаданных

Поле DC	Значение	Язык
dc.contributor.author	Арсланова Алиса Наилевна	ru_RU
dc.contributor.author	Хуснуллина Алина Ринатовна	ru_RU
dc.contributor.author	Арсланова Алиса Наилевна	ru_RU
dc.contributor.author	Хуснуллина Алина Ринатовна	ru_RU
dc.date.accessioned	2026-01-01T00:00:00Z	ru_RU
dc.date.available	2026-01-01T00:00:00Z	ru_RU
dc.date.issued	2026	ru_RU
dc.identifier.citation	A. Arslanova; A. Khusnullina; H. Goto; K. Kimura; Y. Yamamoto; T. Takamura. Cilostazol ameliorates liver fibrosis in a MASLD animal model; potential involvement of liver sinusoidal endothelial cell protection. MASLDモデルにおけるシロスタゾールの肝線維化改善と肝類洞内皮細胞保護の可能性. Abstracts. 39th Annual Scientific Meeting of the Japanese Society for Diabetes and Obesity in Animals. p.79 (82)	ru_RU
dc.identifier.uri	https://repository.kpfu.ru/?p_id=324338	ru_RU
dc.description.abstract	Metabolic dysfunction-associated steatotic liver disease (MASLD) ? and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH) ? leads to injury of liver sinusoidal endothelial cells (LSECs) as a key driver of disease progression. The integrity of LSECs is essential for hepatic microvascular homeostasis, and their dysfunction may exacerbate parenchymal injury and fibrogenesis. Cilostazol, a phosphodiesterase-3 inhibitor, has demonstrated endothelial protective effects, enhancing endothelial function, reducing apoptosis, and modulating vasoactive mediators such as nitric oxide. However, it remains unknown whether cilostazol can similarly protect LSECs and thereby attenuate hepatic fibrosis in MASLD/MASH. We therefore investigated whether cilostazol mitigates liver fibrosis in a murine MASLD model complicated by diabetes, with a particular focus on the preservation of LSEC integrity. Mice were induced to develop MASH plus diabetes by combined feeding of a high-fat d	ru_RU
dc.language.iso	ru	ru_RU
dc.subject	MASLD	ru_RU
dc.subject	MASH	ru_RU
dc.subject	liver fibrosis	ru_RU
dc.subject	type 2 diabetes	ru_RU
dc.subject	cilostazol	ru_RU
dc.title	Cilostazol ameliorates liver fibrosis in a MASLD animal model; potential involvement of liver sinusoidal endothelial cell protection.	ru_RU
dc.type	Тезисы и материалы конференций в зарубежных журналах и сборниках	ru_RU